Arecor Therapeutics plc
(“Arecor”, the “Company” or the “Group”)
EXCLUSIVE FORMULATION STUDY COLLABORATION WITH PAR STERILE PRODUCTS TO DEVELOP A STABLE READY TO USE PRODUCT
Cambridge, UK, 7th June 2021: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has signed a formulation study agreement with Par Sterile Products, LLC, an Endo International plc company (“Par”).
Click here to view the June 2021 edition of eNews - an ON Helix preview.
Uppsala, Sweden June 7th 2021, - LINK Medical, a full-service contract research organization (CRO) providing product development and post-marketing services for the pharmaceutical and medical device industries, has signed a contract to join forces with Insife, an expert consulting and technology service provider for safety and pharmacovigilance organizations.
In this special edition of PharmaVentures Insights, Dr Fintan Walton, CEO & Founder of
Transine Therapeutics (‘Transine’), a biotechnology company developing a novel class of therapeutic RNAs based on its pioneering SINEUP® platform technology, announces that it successfully secured £9.1 million in seed funding. The financing was co-led by Takeda Ventures, Inc.
AMSBIO reports upon a publication** that cites how its STEM-CELLBANKER® animal-free cryopreservation media has played a role in the development of a cell therapy for Parkinson’s Disease that will soon be going into clinical trials.
Alderley Park, Cheshire Infex Therapeutics has today announced a deal with Alderley Analytical, to support PK and ADA analysis of Infex’s RESP-X program.